Aripiprazole: A new atypical antipsyhotic drug;Yeni Kuşak antipsikotiklerden aripiprazol: Bir gözden geçirme

Klinik Psikofarmakoloji Bulteni

Volumn 15, Issue 4, 2005, Pages 198-203

  Monkul, E Serap ^a,b   Akdede, Berna Binnur ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Aripiprazole; Atypical antipsychotics; Partial dopamine agonists

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; HALOPERIDOL; PLACEBO; RISPERIDONE;

CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; REVIEW; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 31644451514     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R, Haddad PM, Hunter R, Taylor DM, Young AH. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005; 59: 485-495
2. Bolonna AA, Kerwin RW. Partial agonism and schizophrenia. Br J Psychiatry 2005; 186: 7-10
3. Stahl SM. Essential Psychopharmacology : neuroscientific basis and practical applications. 2nd Edition. Cambridge University Press 2000, Cambridge UK, pages:77-87
4. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520
5. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293
6. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669
7. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109: 411-420
8. Grunder G, Carlsson A, Wong D. Mechanisms of new antipsychotic medications. Arch Gen Psychiatry 2003; 60: 974-977
9. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human D2 dopamine receptors. J Pharmacol Exp Ther 2002; 302: 381-389
10. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26:649-666
11. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137-140
12. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. 'Goldilocks' actions at dopamine receptors. J Clin Psychiatry 2001; 62: 841-842
13. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21 (suppl 2): 106S-115S
14. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005; 45: 89-93
15. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771
16. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690
17. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 (suppl 18): 47-56
18. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136
19. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-1056
20. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG; Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166: 391-399
21. Keck PEJr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G, and the Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-1658
22. Bourin M, Auby P, Swanink R et al. Aripiprazole vs haloperidol for maintained treatment effect in acute mania.156th Annual Meeting of the American Psychiatric Association. 17-22 Mayis, 2003, San Francisco, California
23. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005; 66:49-51
24. Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20: 9-11
25. Naber D & Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1213-1219
26. Stock E, Saha A, Brunell L, et al. Meta-analysis of cardiac safety with aripiprazole. Int J Neuropsychopharmacol 2002: 5 (Suppl): S186
27. Abilify (aripiprazol) [prospektüs]. Princeton. NJ: Bristol-Meyers Squibb, Aǧustos 2003